放疗后巨噬细胞排除(MERT):提高放疗治疗比的新有效途径
本文综述多项临床前研究及首个人体临床试验,探讨新诊断胶质母细胞瘤(GBM)患者放疗后肿瘤相关巨噬细胞(TAM)浸润的意义。研究表明放疗后骨髓来源TAM积聚可刺激血流恢复并促进肿瘤复发,SDF-1/CXCR4趋化因子通路是关键机制之一。阻断该通路(如CXCR4拮抗剂plerixafor)可增强肿瘤放疗反应并保护正常组织;临床试验验证了plerixafor联合标准治疗可减少照射部位血流并显著改善局部控制。
要点
- 放疗后TAM积聚通过恢复血流促进肿瘤复发,SDF-1/CXCR4通路是关键驱动机制。
- 阻断TAM积聚可同时增强肿瘤放疗反应并保护受照正常组织。
- plerixafor联合标准治疗在GBM临床试验中减少照射部位血流并显著改善局部控制。
核心结论
- 放疗后巨噬细胞排除(MERT)是增强肿瘤放疗反应并保护受照正常组织的有效策略,值得进一步临床试验。
研究设计与样本
- 综述多项临床前研究及一项新诊断胶质母细胞瘤(GBM)患者的首个人体临床试验。
主要发现
- 放疗后受照肿瘤内出现骨髓来源TAM积聚,TAM刺激血流恢复从而促进肿瘤复发。
- TAM积聚的关键机制由SDF-1/CXCR4趋化因子通路驱动,部分肿瘤可能涉及其他通路。
- 阻断该通路防止TAM积聚,既能增强肿瘤放疗反应又能保护受照组织。
- plerixafor联合标准治疗的临床试验显示照射部位血流减少,且相比未用plerixafor的GBM患者局部控制显著改善。
临床怎么用
- 对GBM患者,在标准治疗基础上加用CXCR4拮抗剂plerixafor可能减少照射部位血流并改善局部控制。
局限性
- 本文为综述,证据主要来自临床前研究及一项首个人体临床试验,需进一步临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Here we review a variety of preclinical studies and a first-in-human clinical trial of newly diagnosed glioblastoma (GBM) patients that have investigated the significance of the influx of tumor associated macrophages (TAMs) into tumors after irradiation. We summarize the effects on the response of the tumors and normal tissues to radiation of various agents that either reduce the influx of TAMs into tumors after radiation or change their M1/M2 polarization. The studies show that following irradiation there is an accumulation of bone marrow derived TAMs in the irradiated tumors. These TAMs stimulate the resumption of blood flow in the irradiated tumors thereby promoting recurrence of the tumors. A key mechanism for this accumulation of TAMs is driven by the SDF-1/CXCR4 chemokine pathway though other pathways could also be involved for some tumors. Blocking this pathway to prevent the TAM accumulation in the tumors both enhances tumor response to radiation and protects irradiated tissues. A clinical trial in which the CXCR4 antagonist plerixafor was added to standard therapy of glioblastoma validated the preclinical findings by demonstrating i) reduced blood flow in the irradiated site, and ii) significantly improved tumor local control compared to GBM patients not treated with plerixafor. We conclude that macrophage exclusion after radiation therapy (MERT) is an effective way both to enhance the tumor response to radiation and to protect the irradiated normal tissues. Further clinical trials are warranted.
引用
- Brown JM, Thomas R, Nagpal S, et al. Macrophage exclusion after radiation therapy (MERT): A new and effective way to increase the therapeutic ratio of radiotherapy. Radiother Oncol. 2019. PMID: 31812931. doi:10.1016/j.radonc.2019.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。